<DOC>
	<DOC>NCT01563523</DOC>
	<brief_summary>This trial is conducted in Africa, Asia, Europe, Oceania and North America. The aim of this trial is to evaluate the efficacy of activated recombinant human factor VII given in conjunction with standard therapy in the treatment of massive bleeding in subjects with severe blunt and/or penetrating trauma injury.</brief_summary>
	<brief_title>Efficacy and Safety of Activated Recombinant Human Factor VII in Severely Injured Trauma Patients</brief_title>
	<detailed_description />
	<mesh_term>Wounds and Injuries</mesh_term>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Informed consent obtained from the subject and/or his/her legally authorised representative (LAR) before any trialrelated activities Injury(ies) due to a blunt and or penetrating trauma Receipt of 6 units of PRBC within a 4 hour period following admittance to the trauma centre Receipt of 8 units of PRBC upon administration of trial drug Prehospital cardiac arrest Cardiac arrest in the ER or OR Gunshot wound to the head Glasgow Coma Scale below 8 Base deficit of above 15 mEq/l or severe acidosis Transfusion of 8 units or more of PRBC prior to arrival in trauma centre</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>